Sanofi Aventis Us Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SANOFI AVENTIS US, and when can generic versions of SANOFI AVENTIS US drugs launch?
SANOFI AVENTIS US has one hundred and twenty-two approved drugs.
There are ten US patents protecting SANOFI AVENTIS US drugs.
There are two hundred and seventeen patent family members on SANOFI AVENTIS US drugs in fifty-two countries and one hundred and fifteen supplementary protection certificates in nineteen countries.
Summary for Sanofi Aventis Us
International Patents: | 217 |
US Patents: | 10 |
Tradenames: | 97 |
Ingredients: | 85 |
NDAs: | 122 |
Drugs and US Patents for Sanofi Aventis Us
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | SLO-PHYLLIN | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 085205-001 | May 24, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sanofi Aventis Us | PHISOHEX | hexachlorophene | EMULSION;TOPICAL | 008402-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sanofi Aventis Us | NICOLAR | niacin | TABLET;ORAL | 083823-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sanofi Aventis Us | VANOBID | candicidin | TABLET;VAGINAL | 061613-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sanofi Aventis Us | DANOCRINE | danazol | CAPSULE;ORAL | 017557-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sanofi Aventis Us | HYGROTON | chlorthalidone | TABLET;ORAL | 012283-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sanofi Aventis Us
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | DIABETA | glyburide | TABLET;ORAL | 017532-003 | May 1, 1984 | 3,454,635 | ⤷ Try a Trial |
Sanofi Aventis Us | PENETREX | enoxacin | TABLET;ORAL | 019616-004 | Dec 31, 1991 | 4,352,803 | ⤷ Try a Trial |
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;INTRAVENOUS | 201023-001 | Jun 17, 2010 | 5,847,170*PED | ⤷ Try a Trial |
Sanofi Aventis Us | PLAVIX | clopidogrel bisulfate | TABLET;ORAL | 020839-002 | Sep 20, 2007 | 4,847,265*PED | ⤷ Try a Trial |
Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-001 | Mar 29, 1993 | 4,692,435 | ⤷ Try a Trial |
Sanofi Aventis Us | BRICANYL | terbutaline sulfate | INJECTABLE;INJECTION | 017466-001 | Approved Prior to Jan 1, 1982 | 4,011,258 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANOFI AVENTIS US drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 300 mg/25 mg | ➤ Subscribe | 2006-06-06 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2013-07-01 |
➤ Subscribe | Injection | 5 mg/mL, 10 mL and 20 mL vials | ➤ Subscribe | 2007-02-09 |
➤ Subscribe | Injection | 200 mg/40 mL | ➤ Subscribe | 2007-07-16 |
➤ Subscribe | Injection | 100 mg/mL, 3 mL vials | ➤ Subscribe | 2006-12-07 |
➤ Subscribe | Extended-release Tablets | 12.5 mg | ➤ Subscribe | 2006-01-19 |
➤ Subscribe | Tablets | 150 mg/12.5 mg and 300 mg/12.5 mg | ➤ Subscribe | 2004-11-10 |
➤ Subscribe | Tablets | 75 mg, 150 mg and 300 mg | ➤ Subscribe | 2004-05-25 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-03-04 |
➤ Subscribe | Injection | 40 mg/mL, 0.5 mL and 2 mL vials | ➤ Subscribe | 2009-06-30 |
➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2007-02-09 |
➤ Subscribe | Injection | 5 mg/mL, 40 mL vial | ➤ Subscribe | 2011-03-23 |
➤ Subscribe | Extended-release Tablets | 6.25 mg | ➤ Subscribe | 2006-02-24 |
➤ Subscribe | Tablets | 7 mg and 14 mg | ➤ Subscribe | 2016-09-12 |
International Patents for Sanofi Aventis Us Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2625731 | ⤷ Try a Trial |
China | 104784187 | ⤷ Try a Trial |
South Korea | 20120093986 | ⤷ Try a Trial |
Russian Federation | 2342373 | ⤷ Try a Trial |
Eurasian Patent Organization | 025017 | ⤷ Try a Trial |
Dominican Republic | P2012000118 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sanofi Aventis Us Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1110543 | 08C0004 | France | ⤷ Try a Trial | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
1381356 | PA2014004,C1381356 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: TERIFLUNOMIDUM; REGISTRATION NO/DATE: EU/1/13/838/001-005 20130826 |
2236132 | CA 2015 00004 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718 |
2768484 | LUC00135 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827 |
1667986 | 636 | Finland | ⤷ Try a Trial | |
1381356 | CA 2014 00005 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TERIFLUNOMID, DETS STEREOISOMER OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/13/838/001-005 20130826 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.